| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Izeltabart tapatansine | IMGC-936 | Phase 2 Clinical | Immunogen Inc | Solid tumours | Details |
| DB-1317 | DB-1317 | Phase 1 Clinical | Duality Biologics (Suzhou) Co Ltd | Neoplasm Metastasis; Solid tumours | Details |
| MGC-028 | MGC028; MGC-028 | Phase 1 Clinical | Macrogenics Inc | Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |